Phio Pharmaceuticals Corp. announced on July 25, 2025, that it has entered into a comprehensive drug substance development services agreement with a U.S. manufacturer. This agreement covers the contract development and manufacturing of PH-762, the company's lead INTASYL siRNA compound.
PH-762 is a clinical-stage biopharmaceutical compound that utilizes Phio's proprietary INTASYL gene silencing technology. It is designed to eliminate cancer by making the body's immune cells more effective. Securing a domestic manufacturing source is a critical step in ensuring the reliable supply of this key therapeutic candidate.
This agreement is vital for supporting the ongoing Phase 1b clinical trial of PH-762 and for future clinical and potential commercial needs. It helps to de-risk the development pathway by establishing a robust supply chain for the drug substance, demonstrating operational progress in bringing PH-762 closer to patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.